Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Pitavastatin.

R Y A Mukhtar1, J Reid, J P D Reckless

  • 1Diabetes and Lipid Research, Wolfson Centre, Royal United Hospital, Coombe Park, Bath BA1 3NG, UK.

International Journal of Clinical Practice
|April 28, 2005
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Fluid infusion during postpartum hemorrhage: a secondary analysis of the Obstetric Bleeding Study (OBS) Plus prospective observational study.

International journal of obstetric anesthesia·2026
Same author

A qualitative exploration of cAregiver experienCes Of conseRvatively maNaged kidney failure: the ACORN study.

BMC nephrology·2025
Same author

Effectiveness of interventions for informal caregivers of people with end-stage chronic illness: a systematic review.

Systematic reviews·2024
Same author

Use of multiple pharmacodynamic measures to deconstruct the Nix-TB regimen in a short-course murine model of tuberculosis.

Antimicrobial agents and chemotherapy·2024
Same author

Effect of woodchip bedding during wet conditions on feedlot cattle productivity, behaviour and relative adrenal gland weight.

Animal : an international journal of animal bioscience·2023
Same author

Use of Multiple Pharmacodynamic Measures to Deconstruct the Nix-TB Regimen in a Short-Course Murine Model of Tuberculosis.

bioRxiv : the preprint server for biology·2023
Same journal

RETRACTION: Prediction of Arrhythmia Recurrence after Atrial Fibrillation Ablation in Patients with Normal Anatomy of the Left Atrium.

International journal of clinical practice·2025
Same journal

Clinical Outcomes Based on the Attainment of Low-Density Lipoprotein Cholesterol Targets in Patients with Acute Coronary Syndrome in Real-World Practice.

International journal of clinical practice·2025
Same journal

Knowledge and Awareness of Osteoporosis: A Survey of Physical Therapy Providers in Saudi Arabia.

International journal of clinical practice·2024
Same journal

Efficacy and Safety of Pericapsular Nerve Group Block for Hip Fracture Surgery under Spinal Anesthesia: A Meta-Analysis.

International journal of clinical practice·2024
Same journal

The Role of Pharmaceutical Innovation in Clinical Practice Guidelines for Chronic Diseases.

International journal of clinical practice·2024
Same journal

Blood Features Associated with Viral Infection Severity: An Experience from COVID-19-Pandemic Patients Hospitalized in the Center of Iran, Yazd.

International journal of clinical practice·2024
See all related articles

Pitavastatin is a new statin effective for lowering low-density lipoprotein (LDL)-cholesterol. Its minimal metabolism via cytochrome P450 enzymes may reduce drug interactions, offering a potentially safer alternative.

Area of Science:

  • Pharmacology
  • Cardiovascular Medicine

Background:

  • Intensive lowering of cholesterol, particularly LDL-cholesterol, is crucial, driving demand for effective lipid-lowering agents.
  • Statins are primary agents, but new options are needed to improve efficacy and safety profiles.
  • Pitavastatin, a synthetic HMG-CoA reductase inhibitor, is available in Japan.

Purpose of the Study:

  • To introduce pitavastatin as a novel statin agent.
  • To highlight its metabolic profile and potential for reduced drug-drug interactions.
  • To compare its efficacy in lowering LDL-cholesterol with other statins.

Main Methods:

  • Review of existing human and animal studies on pitavastatin.
  • Analysis of pitavastatin's metabolic pathways, focusing on cytochrome P450 (CYP) enzyme involvement.

Related Experiment Videos

  • Comparison of reported LDL-cholesterol lowering effects with other statins.

    • Main Results:

    • Pitavastatin is a synthetic HMG-CoA reductase inhibitor.
    • Its metabolism is minimal, primarily via CYP 2C9, with limited CYP 3A4 involvement.
    • Preliminary studies suggest pitavastatin may be as effective as rosuvastatin in lowering LDL-cholesterol.

    Conclusions:

    • Pitavastatin presents a potentially advantageous metabolic profile, minimizing drug-drug interaction risks.
    • It shows promise as an effective agent for lowering LDL-cholesterol.
    • Further head-to-head clinical trials are needed to confirm its comparative efficacy and safety.